Heba Banat

Dr. Heba Banat

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Heba BanatHeba Banat
Heba Banat
Ildikó CsókaIldikó Csóka
Ildikó Csóka
Dóra ParóczaiDóra Paróczai
Dóra Paróczai
Katalin BuriánKatalin Burián
Katalin Burián
ÁFÁrpád Farkas
Árpád Farkas
Rita AmbrusRita Ambrus
Rita Ambrus
Pulmonary inflammations such as chronic obstructive pulmonary disease and cystic fibrosis are widespread and can be fatal, especially when they are characterized by abnormal mucus accumulation. Inhaled corticosteroids are commonly used for lung inflammations despite their considerable side effects. By utilizing particle engineering techniques, a combined dry powder inhaler (DPI) comprising nanosized ketoprofen-embedded mannitol-coated microparticles was developed. A nanoembedded microparticle system means a novel advance in pulmonary delivery by enhancing local pulmonary deposition while avoiding clearance mechanisms. Ketoprofen, a poorly water-soluble anti-inflammatory drug, was dispersed in the stabilizer solution and then homogenized by ultraturrax. Following this, a ketoprofen-containing nanosuspension was produced by wet-media milling. Furthermore, co-spray drying was conducted with L-leucine (dispersity enhancer) and mannitol (coating and mucuactive agent). Particle size, morphology, dissolution, permeation, viscosity, in vitro and in silico deposition, cytotoxicity, and anti-inflammatory effect were investigated. The particle size of the ketoprofen-containing nanosuspension was ~230 nm. SEM images of the spray-dried powder displayed wrinkled, coated, and nearly spherical particles with a final size of ~2 µm (nano-in-micro), which is optimal for pulmonary delivery. The mannitol-containing samples decreased the viscosity of 10% mucin solution. The results of the mass median aerodynamic diameter (2.4–4.5 µm), fine particle fraction (56–71%), permeation (five-fold enhancement), and dissolution (80% release in 5 min) confirmed that the system is ideal for local inhalation. All samples showed a significant anti-inflammatory effect and decreased IL-6 on the LPS-treated U937 cell line with low cytotoxicity. Hence, developing an innovative combined DPI comprising ketoprofen and mannitol by employing a nano-in-micro approach is a potential treatment for lung inflammations.

28 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Heba BanatHeba Banat
Heba Banat
ANAttila Tibor Nagy
Attila Tibor Nagy
ÁFÁrpád Farkas
Árpád Farkas
Rita AmbrusRita Ambrus
Rita Ambrus
Ildikó CsókaIldikó Csóka
Ildikó Csóka
Background: Nanocrystals, a carrier-free nanotechnology, offer significant advantages for pulmonary drug delivery by enhancing the dissolution and solubility of poorly soluble drugs while maintaining favorable biological properties and low toxicity. This study aims to investigate the aerodynamic performance and stability of nanocrystal-based dry powders (NC-DPs). Methods: Nanocrystalline suspensions were produced via wet media milling and subjected to stability studies before undergoing nano spray drying. A factorial design was employed to optimize the process parameters. The influence of mannitol and leucine, individually and in combination, was evaluated in terms of aerodynamic properties (Aerodynamic Particle Sizer (APS), in silico modeling) and the physicochemical stability at room temperature (in a desiccator) and accelerated conditions (40 ± 2 °C, 75 ± 5% relative humidity). Results: APS analysis revealed that leucine-containing powders (K-NC-Ls) exhibited the smallest median (1.357 µm) and geometric mean (1.335 µm) particle sizes, enhancing dispersibility. However, in silico results indicated the highest exhaled fraction for K-NC-L, highlighting the need for optimized excipient selection. Although mannitol showed the lowest exhaled fraction, it was mainly deposited in the extra-thoracic region in silico. The mannitol/leucine combination (K-NC-ML) revealed a low exhaled fraction and high lung deposition in silico. Also, K-NC-ML demonstrated superior stability, with a 6% reduction in D[0.5] and a 5% decrease in span overtime. Furthermore, no significant changes in crystallinity, thermal behavior, drug release, or mass median aerodynamic diameter were observed under stress conditions. Conclusions: These findings confirm that combined incorporation of mannitol and leucine in NC-DP formulations enhances stability and aerodynamic performance, making it a promising approach for pulmonary drug delivery.

3 February 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Heba BanatHeba Banat
Heba Banat
IGIlona Gróf
Ilona Gróf
Maria DeliMaria Deli
Maria Deli
Rita AmbrusRita Ambrus
Rita Ambrus
Ildikó CsókaIldikó Csóka
Ildikó Csóka
Pulmonary drug delivery presents a promising approach for managing respiratory diseases, enabling localized drug deposition and minimizing systemic side effects. Building upon previous research, this study investigates the cytotoxicity, permeability, and stability of a novel carrier-free dry powder inhaler (DPI) formulation comprising nanosized ketoprofen (KTP) and mannitol (MNT). The formulation was prepared using wet media milling to produce KTP-nanosuspensions, followed by spray drying to achieve combined powders suitable for inhalation. Cell viability and permeability were conducted in both alveolar (A549) and bronchial (CFBE) models. Stability was assessed after storage in hydroxypropyl methylcellulose (HPMC) capsules under stress conditions (40 °C, 75% RH), as per ICH guidelines. KTP showed good penetration through both models, with lower permeability through the CFBE barrier. The MNT-containing sample (F1) increased permeability by 1.4-fold in A549. All formulations had no effect on cell barrier integrity or viability after the impedance test, confirming their safety. During stability assessment, the particle size remained consistent, and the partially amorphous state of KTP was retained over time. However, moisture absorption induced surface roughening and partial agglomeration, leading to reduced fine particle fraction (FPF) and emitted fraction (EF). Despite these changes, the mass median aerodynamic diameter (MMAD) remained stable, confirming the formulation’s continued applicability for pulmonary delivery. Future research should focus on optimizing excipient content, alternative capsule materials, and storage conditions to mitigate moisture-related issues. Hence, the findings demonstrate that the developed ketoprofen–mannitol DPI retains its quality and performance characteristics over an extended period, making it a viable option for pulmonary drug delivery.

19 April 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
Heba BanatHeba Banat
Heba Banat
ICIldikó Csóka
Ildikó Csóka
FKFruzsina Kun-Szabó
Fruzsina Kun-Szabó
GFGergely H. Fodor
Gergely H. Fodor
PSPetra Somogyi
Petra Somogyi
Rita AmbrusRita Ambrus
Rita Ambrus
Pulmonary administration offers a promising needle-free approach for systemic delivery of nonsteroidal anti-inflammatory drugs (NSAIDs), improving bioavailability and reducing required doses. While mannitol and leucine are widely used in inhalation formulations, their potential to enhance systemic drug delivery via the pulmonary route remains largely unexplored. This study utilizes the nanocrystal agglomerates (NCAs) approach to develop an inhalable NSAID formulation, with ketoprofen (KTP) as a model drug. Wet media milling and nano spray drying were employed for NCA fabrication, and the roles of mannitol and leucine were evaluated individually and in combination. Notably, their combination exhibited synergy, overcoming limitations observed with individual excipients. Mannitol-based sample (K1M) reduced aerosol performance by increasing the mass median aerodynamic diameter (MMAD) to 4.5 µm, whereas leucine-based sample (K1L) improved aerosolization but resulted in a low MMAD (<1 µm), suggesting a high tendency for exhalation. The combined mannitol-leucine formulation (K1ML) achieved optimal aerosol performance, balancing dispersibility and controlled deposition. K1ML also exhibited the fastest drug release (99 % in 5 min) and enhanced permeability across the alveolar barrier while maintaining biocompatibility. Pharmacokinetic analysis confirmed that inhaled K1ML provided superior bioavailability (AUC 73 µg·h/mL) compared to oral KTP nanosuspension (42 µg·h/mL) and raw KTP (9 µg·h/mL). Nonetheless, prolonged inhalation in asthmatic models (ovalbumin-sensitised rats) impaired pulmonary function, emphasizing the need for dose optimization. These findings demonstrate that the mannitol-leucine combination in NCAs enhances systemic NSAID delivery, optimizing both aerosol performance and bioavailability. Future studies should refine dosing strategies to ensure long-term safety and clinical feasibility.